共 50 条
- [31] A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell MalignanciesCANCER IMMUNOLOGY RESEARCH, 2021, 9 (01) : 50 - 61de Weerdt, IrisLameris, RoelandScheffer, George L.Vree, Janade Boer, RenateStam, Anita G.van de Ven, RienekeLevin, Mark-DavidPals, Steven T.Roovers, Rob C.Parren, Paul W. H., Ide Gruijl, Tanja D.Kater, Arnon P.van der Vliet, Hans J.
- [32] Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell MalignanciesBLOOD, 2013, 122 (21)Forero-Torres, AndresHamadani, MehdiFanale, Michelle A.Bello, Celeste M.Kipps, Thomas J.Offner, FritzVerhoef, GregorFederico, MassimoGregory, Stephanie A.Sonet, AnneAssouline, SaritPerez de Oteyza, JaimeTomas, Jose FranciscoCuneo, AntonioElgeioushi, NairouzGoswami, TrishnaIbrahim, RamyHerbst, RonaldCheson, Bruce D.
- [33] Epratuzumab (hLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin's lymphoma (NHL).BLOOD, 2000, 96 (11) : 578A - +Leonard, JPColeman, MChadburn, AMatthews, JCBayer, RLSchuster, MWFeldman, EJJuweid, MSchuster, SJWegener, WAGoldenberg, DM
- [34] A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell MalignanciesBLOOD, 2023, 142Mazza, Irit AviviBarba, PereYuda, JunichiroPalomba, Maria LiaAlderuccio, Juan Pablode Vriendt, CielCorradini, PaoloLim, Francesca Lorraine Wei InngZinzani, Pier LuigiJain, NitinLeonard, Jessica T.Coulson, MichelleHassounah, NadiaYang, XiaolingLu, HaihuiLewandowski, AndrewPolli, Joseph RyanKlopfenstein, MatthieuPastore, AlessandroBrisou, Gabriel
- [35] First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Brownstein, Carrie M.Adriaens, LieveBannerji, RajatChavez, Julio C.Levy, RonaldAnsell, Stephen MaxtedAdvani, Ranjana H.Patel, SnehalKostic, AnaTrail, PamelaLowy, IsraelKohrt, Holbrook Edwin
- [36] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)BLOOD, 2019, 134Bannerji, RajatAllan, John N.Arnason, Jon E.Brown, Jennifer R.Advani, Ranjana H.Barnes, Jeffrey A.Ansell, Stephen M.O'Brien, Susan M.Chavez, JulioDuell, JohannesDavid, Kevin A.Martin, PeterJoyce, Robin M.Charnas, RobertAmbati, Srikanth R.Adriaens, LieveUfkin, MelanieZhu, MinLi, JingjinGasparini, PeterIbrahim, AnfalJankovic, VladimirFiaschi, NathalieAina, OlulanuZhang, WenDeering, Raquel P.Hamon, SaraThurston, GavinMurphy, Andrew J.Weinreich, David M.Yancopoulos, George D.Lowy, IsraelSternberg, DavidTopp, Max S.
- [37] Inhibition of human B-cell lymphoma by an anti-CD20 antibody HI47 and its chimeric Fab and F(ab')2 fragments via induction of apoptosisACTA PHARMACOLOGICA SINICA, 2006, 27 : 437 - 437xiong, DongshengYang, ChunzhengXu, YuanfuFan, Dongmei
- [38] hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.BLOOD, 2016, 128 (22)Zammarchi, FrancescaCorbett, SimonAdams, LaurenMellinas-Gomez, MariaTyrer, PeterDissanayake, SandamaliSims, SimoneHavenith, KarinChivers, SimonWillimas, David G.Howard, Philip W.Hartley, John A.van Berkel, Patrick
- [40] Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBLOOD, 2008, 111 (03) : 1094 - 1100Coiffier, BertrandLepretre, StephanePedersen, Lars MollerGadeberg, OleFredriksen, Henrikvan Oers, Marinus H. J.Wooldridge, JamesKloczko, JanuszHolowiecki, JerzyHellmann, AnrzejWalewski, JanFlensburg, MimiPetersen, JorgenRobak, Tadeusz